USP30 Protein

USP30 Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">USP30 Protein</th>
</tr>
<tr>
<td class="label">Protein</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">Parkin</td>
<td>Substrate antagonism</td>
</tr>
<tr>
<td class="label">MFN1/MFN2</td>
<td>Direct substrate</td>
</tr>
<tr>
<td class="label">TOM complex</td>
<td>Direct substrate</td>
</tr>
<tr>
<td class="label">PINK1</td>
<td>Pathway interaction</td>
</tr>
<tr>
<td class="label">Optineurin</td>
<td>Mitophagy receptor</td>
</tr>
<tr>
<td class="label">NBR1</td>
<td>Mitophagy receptor</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a>, <a href="/wiki/cardiac" style="color:#ef9a9a">Cardiac</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">107 edges</a></td>
</tr>
</table>

USP30 Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">USP30 Protein</th>
</tr>
<tr>
<td class="label">Protein</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">Parkin</td>
<td>Substrate antagonism</td>
</tr>
<tr>
<td class="label">MFN1/MFN2</td>
<td>Direct substrate</td>
</tr>
<tr>
<td class="label">TOM complex</td>
<td>Direct substrate</td>
</tr>
<tr>
<td class="label">PINK1</td>
<td>Pathway interaction</td>
</tr>
<tr>
<td class="label">Optineurin</td>
<td>Mitophagy receptor</td>
</tr>
<tr>
<td class="label">NBR1</td>
<td>Mitophagy receptor</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a>, <a href="/wiki/cardiac" style="color:#ef9a9a">Cardiac</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">107 edges</a></td>
</tr>
</table>

Ubiquitin Specific Peptidase 30 (USP30) is a deubiquitinating enzyme localized to the outer mitochondrial membrane that plays a critical role in regulating mitochondrial quality control through its activity on the PINK1/Parkin mitophagy pathway. As one of the few mitochondrial-specific deubiquitinases, USP30 removes ubiquitin chains from mitochondrial outer membrane proteins, counteracting Parkin-mediated mitophagy and thereby influencing neuronal survival in neurodegenerative diseases, particularly [Parkinson's disease](/diseases/parkinsons-disease).

USP30 has emerged as a promising therapeutic target for [Parkinson's disease](/diseases/parkinsons-disease) and other disorders characterized by mitochondrial dysfunction, with several pharmaceutical companies developing USP30 inhibitors for clinical use.[@kluge2018][@zhang2021]

Structure

USP30 possesses a distinct structural architecture optimized for its mitochondrial function:

Catalytic Domain

• Ubiquitin-specific protease (USP) domain: The C-terminal catalytic domain (~350 amino acids) contains the classic USP fold with finger, thumb, and palm subdomains that coordinate ubiquitin binding and hydrolysis[@bingol2014]
• Active site residues: Catalytic triad (Cys, His, Asp/Asn) essential for deubiquitinating activity[@bingol2014]
• Ubiquitin-interacting motifs (UIMs): Two UIMs facilitate substrate recognition and binding[@bingol2014]

Mitochondrial Targeting

• N-terminal mitochondrial targeting sequence: A hydrophobic transmembrane helix (residues 1-30) anchors USP30 to the outer mitochondrial membrane[@bingol2014]
• Cytoplasmic orientation: The catalytic domain faces the cytoplasm, allowing access to cytosolic ubiquitin[@bingol2014]
• Membrane association: Tight association with the outer mitochondrial membrane via the transmembrane domain[@bingol2014]

Structural Flexibility

• Flexible linker regions: The transmembrane helix connects to the catalytic domain via flexible linkers allowing conformational changes[@bingol2014]
• Post-translational modification sites: Multiple phosphorylation and oxidation sites regulate activity[@kluge2018]

Normal Function

USP30 is a key regulator of mitochondrial quality control through its deubiquitinating activity:

Mitophagy Regulation

• Direct substrate action: Removes ubiquitin from proteins like Mitofusin-1 (MFN1), Mitofusin-2 (MFN2), and TOM complex components[@bingol2014]
• Parkin antagonism: Counteracts Parkin E3 ligase activity by hydrolyzing the ubiquitin chains Parkin adds to damaged mitochondria[@bingol2014]
• Threshold regulation: Controls the sensitivity threshold for mitophagy initiation[@kluge2018]

Mitochondrial Dynamics

• Fusion regulation: Controls ubiquitination status of MFN1/2, key regulators of mitochondrial fusion[@kluge2018]
• Fission modulation: Influences [Drp1](/proteins/drp1-protein)-mediated fission through indirect mechanisms[@riverorios2020]
• Network maintenance: Helps maintain healthy mitochondrial network connectivity[@kluge2018]

Cellular Protection

• Stress response: Provides protection against various mitochondrial stressors[@kluge2018]
• Energy metabolism: Maintains mitochondrial function for ATP production[@riverorios2020]
• [Apoptosis](/entities/apoptosis) regulation: Modulates mitochondrial apoptosis pathways[@riverorios2020]

Role in Neurodegenerative Diseases

Parkinson's Disease

USP30 has emerged as a significant player in [Parkinson's disease](/diseases/parkinsons-disease) pathogenesis:[@bingol2014][@kluge2018][@zhang2021]

PINK1/Parkin Pathway Modulation

• In healthy [neurons](/entities/neurons), PINK1 is constitutively degraded in the mitochondrial inner membrane[@bingol2014]
• Upon mitochondrial damage, PINK1 accumulates on the outer mitochondrial membrane and phosphorylates both ubiquitin and Parkin[@bingol2014]
• Activated Parkin then ubiquitinates mitochondrial proteins, tagging mitochondria for autophagic degradation[@bingol2014]
• USP30 removes these ubiquitin chains, delaying or preventing mitophagy[@bingol2014]

• USP30 gene variants have been associated with [Parkinson's disease](/diseases/parkinsons-disease) risk in genome-wide association studies (GWAS)[@zhang2021]
• Certain USP30 polymorphisms correlate with age of onset[@zhang2021]
• Loss-of-function variants may increase susceptibility to dopaminergic neuron loss[@zhang2021]

• USP30 inhibitors enhance mitophagy and promote clearance of damaged mitochondria[@kluge2018]
• Inhibitors may be particularly beneficial in cases with PINK1 or Parkin mutations[@kluge2018]
• Combination approaches with other mitophagy enhancers are being explored[@zhang2021]

Alzheimer's Disease

While primarily studied in PD, USP30 may play roles in [Alzheimer's disease](/diseases/alzheimers-disease):[@riverorios2020]

• Mitochondrial dysfunction is an early feature of [Alzheimer's disease](/diseases/alzheimers-disease)[@riverorios2020]
• [Amyloid-beta](/proteins/amyloid-beta) and [tau](/proteins/tau) pathology affect mitochondrial quality control[@riverorios2020]
• USP30 activity may influence amyloid-induced mitochondrial damage[@riverorios2020]

Amyotrophic Lateral Sclerosis

Emerging evidence suggests USP30 involvement in [ALS](/diseases/amyotrophic-lateral-sclerosis):[@riverorios2020]

• Mitochondrial dysfunction is a hallmark of ALS[@riverorios2020]
• USP30 modulation may affect motor neuron survival[@riverorios2020]

Interacting Proteins

USP30 interacts with several key proteins involved in mitochondrial quality control:

Therapeutic Targeting

USP30 has become a priority target for neurodegenerative disease therapy:[@kluge2018][@zhang2021]

USP30 Inhibitors

• Small molecule inhibitors: Several compounds (e.g., FT396b5, USP30i) show nanomolar potency[@kluge2018]
• Mechanism: Bind to the active site, blocking ubiquitin hydrolysis[@kluge2018]
• Specificity: Selectivity over other USPs is crucial for therapeutic development[@kluge2018]

Therapeutic Strategies

• Monotherapy: USP30 inhibition alone can enhance baseline mitophagy[@kluge2018]
• Combination therapy: May synergize with Parkin activators or PINK1 stabilizers[@zhang2021]
• Gene therapy: RNA approaches to reduce USP30 expression are being explored[@zhang2021]

Clinical Development

• Preclinical studies in mouse models of PD show promise[@kluge2018]
• [Blood-brain barrier](/entities/blood-brain-barrier) penetration remains a key challenge[@zhang2021]
• Expected to enter clinical trials within the next few years[@zhang2021]

Research Methods

The study of USP30 employs multiple experimental approaches:

• Biochemistry: In vitro deubiquitination assays with purified proteins[@bingol2014]
• Cell biology: Confocal microscopy of mitochondrial morphology and mitophagy markers[@bingol2014]
• Genetics: CRISPR knockout/knockin in cell lines and animal models[@kluge2018]
• Pharmacology: Inhibitor development and testing in disease models[@kluge2018]
• Structural biology: X-ray crystallography and cryo-EM of USP30 structure[@bingol2014]

See Also

• [USP30 Gene](/genes/usp30) — Gene page
• [Mitophagy](/mechanisms/mitophagy) — Mitochondrial [autophagy](/entities/autophagy)
• [PINK1/Parkin Pathway](/mechanisms/pink1-parkin-pathway) — Pathway in PD
• [Mitochondrial Quality Control](/mechanisms/mitochondrial-quality-control) — Overview
• [Parkinson's Disease](/diseases/parkinsons-disease) — Disease page
• [Mitochondrial Dynamics](/mechanisms/mitochondrial-dynamics) — Fusion/fission

External Links

• [UniProt: usp30](https://www.uniprot.org/)
• [PubMed: usp30](https://pubmed.ncbi.nlm.nih.gov/?term=usp30+neurodegeneration)

References